NCT05697913 2024-03-06
Efficacy of Response-adapted Treatment in Patients With Multiple Myeloma Candidates for Bone Marrow Transplantation
Hospital Galdakao-Usansolo
Phase NA Unknown
Clinical Trials
24 trialsNCT06125106 2023-11-09
Prospective, Single-arm, Multicenter Clinical Study on Haploidentical Hematopoietic Stem Cell Transplantation in Patients With MRD Positive CD19+ALL Treated With Conditioning Regimens Containing Blinatumomab
Zhejiang University
Phase 1 Unknown
NCT05956977 2023-07-24
Neuro3DUS
University of Ulm
Phase NA Unknown
NCT03189576 2023-05-26
Measuring Molecular Residual Disease in Colorectal Cancer After Primary Surgery and Resection of Metastases
Tampere University Hospital
Phase NA Unknown
NCT04309084 2023-02-16
Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma
Celularity Incorporated
Phase 1 Unknown
NCT05603156 2022-11-02
A Study of Olverembatinib Combined With Inotuzumab Ozogamicin in the Treatment ph+ ALL With MRD Persistent Positive
Institute of Hematology & Blood Diseases Hospital, China
Phase NA Unknown
NCT03697707 2022-10-10
ADVANCE-II
Mendus
Phase 2 Unknown
NCT05460195 2022-07-15
Sintilimab Combined With Anlotinib for Perioperative Non-small Cell Lung Cancer Based on MRD Evaluation
Shanghai Chest Hospital
Phase 2 Unknown
NCT05362942 2022-05-05
Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid Leukemia
Beijing 302 Hospital
Phase 2 Unknown
NCT04375683 2022-03-24
Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in Ph Positive ALL
Zhongda Hospital
Phase 3 Unknown
NCT04604691 2022-03-08
Blinatumomab in Pediatric B-cell Acute Lymphoblastic Leukemia (ALL) With Minimal Residual Disease (MRD)
Seoul National University Hospital
Phase 1 Unknown
NCT05137860 2022-01-18
Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRD
Hospital General de Mexico
Phase 4 Unknown
NCT05079022 2021-10-15
ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas
Peking University People's Hospital
Phase 1/2 Unknown
NCT01894477 2021-06-03
Treo/Flu/TBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Fred Hutchinson Cancer Center
Phase 2 Unknown
NCT03297528 2020-03-10
Chemotherapy and DLI for Prevention of Second Relapse in Patients With Relapsed Acute Leukemia After Allotransplant
Peking University People's Hospital
Phase 2 Unknown
NCT02670109 2020-01-14
Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment for Triple Negative Breast Cancer Patients
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Phase 2 Unknown
NCT03665480 2018-10-09
The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML
Nanfang Hospital, Southern Medical University
Phase 2/3 Unknown
NCT03662087 2018-09-07
HMA+DLI vs DLI Preemptive Therapy Based on MRD for AL Undergoing Allo-HSCT
Nanfang Hospital, Southern Medical University
Phase 2/3 Unknown
NCT03624530 2018-08-10
Effect of Prophylactic TKI Therapy Post-transplants on Ph+ ALL Undergoing Allo-HSCT With MRD Positive Pre-transplants
Nanfang Hospital, Southern Medical University
Phase 2/3 Unknown
NCT03564977 2018-07-02
CD19-targeted CAR-T Cell Therapy for MRD+ B-cell Malignancies After Autologous Stem Cell Transplantation
Qingdao Central Hospital
Phase NA Unknown
NCT02185261 2018-06-07
Interferon α for the Therapy of Minimal Residual Disease
Peking University People's Hospital
Phase NA Unknown
NCT01883219 2017-11-08
TKI Therapy Based on Molecular Monitoring in Allogeneic-HSCT Recipients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
Nanfang Hospital, Southern Medical University
Phase 2 Unknown
NCT01665001 2012-08-17
Personalized Therapy of Precursor Lymphoid Neoplasms
Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice
Phase 2 Unknown
NCT00551577 2007-10-31
PRIMOVAR-1
University Hospital, Bonn
Phase 2 Unknown